← Leaderboards
Keith T Flaherty
University Of Pennsylvania
$13,209,948
Attributed
$33,560,451
Total exposure
11
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $9.8M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$44,308,990 · 13
By mechanism
UM1$23,631,028 · 1
U54$17,702,468 · 10
R01$2,315,482 · 1
K23$660,012 · 1
Top collaborators
- Ryan Bruce Corcoran13 shared
- Donald W. Kufe13 shared
- Geoffrey I Shapiro13 shared
- Lynda Chin9 shared
- William M Lee5 shared
- Katherine L Nathanson5 shared
- Arlene H Sharpe3 shared
- Phillip Andrew Futreal2 shared
Most similar at University Of Pennsylvania
Same institution · by research overlap
- Wendy K Rathmell$9,818,166
- Charles P Emerson$35,198,488
- Katherine L Nathanson$24,205,332
- M. Celeste Simon$38,172,459
- Paul G Corn$1,308,057
Others in their field
Top investigators on “Resistance”
- Judith S. Currier · University Of California Los Angeles$243,611,225
- Gregory H Reaman · National Childhood Cancer Foundation$217,720,574
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$180,092,958
- Ralph Parchment · Leidos Biomedical Research, Inc.$149,556,948
- Wafaa M. El-Sadr · Columbia University Health Sciences$113,991,858
- Peter C Adamson · National Childhood Cancer Foundation$113,790,601
Research focus
ResistanceResponseTumorMalignant NeoplasmsInhibitor/AntagonistClinical TrialsMutationMelanomaMolecularNeoplastic CellResistance MechanismCellsGenomicsPathway InteractionsBraf GeneSignal TransductionBaseMutantSpecimenCancer Therapy Evaluation ProgramProgramsDrug ResistanceSamplingSite
Grant awards (54)
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$2,074,014
UM1 · FY2025 · CA
DF/HCC Preclinical Translation-Focused Clinical Investigator to Bridge PDXNet and the ETCTN$194,240
UM1 · FY2025 · CA
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$1,970,313
UM1 · FY2024 · CA
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$2,555,380
UM1 · FY2023 · CA
An integrated translational approach to overcome drug resistance$1,224,938
U54 · FY2021 · CA
Project-003$486,160
U54 · FY2021 · CA
Project-002$463,293
U54 · FY2021 · CA
Project 2$275,485
U54 · FY2021 · CA
XPO1 inhibitors Selinexor and Eltanexor in Combination with Venetoclax and Decitabine (ASTX727) in AML$124,999
UM1 · FY2021 · CA
Dana-Farber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site) - Incorporation of Mayo Clinic Cancer Center as an Affiliated Center$100,000
UM1 · FY2021 · CA
DanaâFarber/Harvard Cancer Center Experimental Therapeutics Clinical Trials Network Site (DF/HCC ETCTN Site)$6,942,412
UM1 · FY2020 · CA
An integrated translational approach to overcome drug resistance$1,356,228
U54 · FY2020 · CA
Project-003$559,613
U54 · FY2020 · CA
Project-002$517,329
U54 · FY2020 · CA
Project 2$399,609
U54 · FY2020 · CA
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$2,325,303
UM1 · FY2019 · CA
An integrated translational approach to overcome drug resistance$1,239,225
U54 · FY2019 · CA
Project-003$511,159
U54 · FY2019 · CA
Project-002$435,748
U54 · FY2019 · CA
Project 2$292,318
U54 · FY2019 · CA
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,952,701
UM1 · FY2018 · CA
An integrated translational approach to overcome drug resistance$2,500,407
U54 · FY2017 · CA
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,765,337
UM1 · FY2016 · CA
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$713,143
UM1 · FY2016 · CA
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,513,183
UM1 · FY2015 · CA
Role of Tumor Stroma in Therapeutic Response and Resistance$843,318
U54 · FY2015 · CA
Role of Immune Regulatory Pathways in BRAF targeted therapy In melanoma$291,084
U54 · FY2015 · CA
Role of Tumor in Therapeutic Response and Resistance$261,117
U54 · FY2015 · CA
Clinically Annotated Human Melanoma for TMEN Research$197,279
U54 · FY2015 · CA · contact PI
Genetically Engineered Mouse Models for TMEN Research$93,838
U54 · FY2015 · CA
Dana-Farber/Harvard Cancer Center ET-CTN with Phase I Emphasis$1,400,003
UM1 · FY2014 · CA
Role of Tumor Stroma in Therapeutic Response and Resistance$827,411
U54 · FY2014 · CA
Role of Immune Regulatory Pathways in BRAF targeted therapy In melanoma$288,077
U54 · FY2014 · CA
Role of Tumor in Therapeutic Response and Resistance$254,210
U54 · FY2014 · CA
Clinically Annotated Human Melanoma for TMEN Research$194,008
U54 · FY2014 · CA · contact PI
Genetically Engineered Mouse Models for TMEN Research$91,116
U54 · FY2014 · CA
Role of Tumor Stroma in Therapeutic Response and Resistance$954,554
U54 · FY2013 · CA
Role of Tumor in Therapeutic Response and Resistance$451,222
U54 · FY2013 · CA
Genotype and phenotype predictors in therapy response in renal cell carcinoma$421,339
R01 · FY2013 · CA
Regulatory T Cell Compartment$304,487
U54 · FY2013 · CA
Human Specimens$291,348
U54 · FY2013 · CA · contact PI
Human Specimens$129,794
U54 · FY2013 · CA
Role of Tumor Stroma in Therapeutic Response and Resistance$872,340
U54 · FY2012 · CA
Genotype and phenotype predictors in therapy response in renal cell carcinoma$447,222
R01 · FY2012 · CA
Clinically Annotated Human Melanoma for TMEN Research$165,635
U54 · FY2012 · CA · contact PI
Role of Tumor Stroma in Therapeutic Response and Resistance$930,118
U54 · FY2011 · CA
Genotype and phenotype predictors in therapy response in renal cell carcinoma$449,030
R01 · FY2011 · CA
Genotype and phenotype predictors in therapy response in renal cell carcinoma$489,269
R01 · FY2010 · CA
Genotype and phenotype predictors in therapy response in renal cell carcinoma$508,622
R01 · FY2009 · CA
Combination Strategies for Angiogenesis Inhibition$132,364
K23 · FY2008 · CA · contact PI
Combination Strategies for Angiogenesis Inhibition$132,177
K23 · FY2007 · CA · contact PI
Combination Strategies for Angiogenesis Inhibition$131,997
K23 · FY2006 · CA · contact PI
Combination Strategies for Angiogenesis Inhibition$131,822
K23 · FY2005 · CA
Combination Strategies for Angiogenesis Inhibition$131,652
K23 · FY2004 · CA